SLXP Xifaxan rifaximin vs SNTS Rifamycin SV MMX and RUCONEST SAN 300
As per the SNTS
Clinical activity in infectious diarrhea appears comparable to Xifaxan®
SLXP makes per quarter $150.6 million x 4 = $600M yearly
FDA approval hepatic encephalopathy
Salix is also looking to develop an extended intestinal release (:EIR) version of rifaximin for Crohn’s disease. Patient enrolment in two phase III studies is expected to commence in the second half of the year.
SNTS should be able to grab $15M per quarter as starter
that would be another $60M / year on $350 + $50M = $400M
and RUCONEST another $15M / Quarter that would give $450M / year with 0 growth and min sales
Not included acute pancreatitis for Ruconest which has a huge market.
SNTS has market cap of $1.6Billion market cap and should be atleast $5 Billion market after Rifamycin and Ruconest
do a google on
Rifamycin SV MMX Diverticulitis
Rifamycin SV MMX®; whether the FDA ultimately approves the NDA ..... Potential Indications ▫ Diverticulitis, HE, IBD, CDAD. ▫ HE, IBS, CD, CDAD. Page 30. 30. Includes all indications for which Ciprofloxacin & Xifaxan® are
Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis